GSK

Over one million people develop shingles in Japan each year1,2 New presentation offers convenient administration of GSK's shingles vaccine GSK plc (LSE/NYSE: GSK) today announced Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a prefilled syringe presentation of Shingrix (GSK’s Recombinant Zoster Vaccine or RZV) for the prevention of shingles (herpes zoster).

Issued: London, UK For media and investors only Results showed higher immune responses versus standard and high dose flu vaccines in younger and older adults respectively1 Vaccine candidate designed to target the two primary surface antigens that cause flu viruses to bind and spread Phase III trial to start in September 2026 GSK plc (LSE/NYSE: GSK) presented positive phase II data for its mRNA seasonal influenza (flu) vaccine candidate at the OPTIONS XIII Conference for the Control of Influenza.

GSK Science in the Summer began in Philadelphia forty years ago, created by retired GSK scientist Dr. Virginia Cunningham to encourage young people to pursue STEM careers. Since then, the program led by The Franklin Institute has reached more than 400,000 youth across the U.S., bringing high-quality, accessible STEM learning into communities nationwide. GSK Science in the Summer makes STEM exciting, giving students hands-on experience and career inspiration.

First global approval for Hibsago Chronic hepatitis B affects nearly one million people in Japan1 with nationwide efforts for screening and treatment2 Approval accelerated by SENKU designation, granted to innovative medicines with potential to address high unmet medical need3 GSK plc (LSE/NYSE: GSK) today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Hibsago (bepirovirsen), an antisense oligonucleotide (ASO), as a functional cure for chronic hepatitis B...

Submission supported by AZUR-1 data showing significant proportion of participants with no detectable signs of cancer one year or more after treatment If approved, Jemperli could eliminate the need for chemotherapy, radiation, and surgery for some patients Application accepted under Project Orbis, an initiative to potentially expedite approvals through coordinated international regulatory reviews GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has accepted...

3 min read time Life Unpaused: How Senior Athletes Stay in the Game We are at the National Senior Games, the largest multi-sport qualifying event in the world — bigger than the Olympics! More than 12,000 athletes competed in Des Moines, Iowa, redefining what’s possible for us as we age.

機能的治癒の達成割合の改善を示した主要な第III相試験（B-Well 1、B-Well 2試験）の結果1に基づく承認 先駆的医薬品指定制度による指定品目2として初の承認 日本ではB型肝炎ウイルス（HBV）持続感染の患者数は約100万人と推計されており3、HBV持続感染は肝がんの主要原因のひとつとされる4 グラクソ・スミスクライン株式会社（本社：東京都港区、代表取締役社長：ポール・リレット、以下GSK）は、本日、「ヒブサーゴ皮下注150mgシリンジ（一般名：ベピロビルセンナトリウム、以下べピロビルセン）」、について、B型肝炎ウイルス（Hepatitis B virus：HBV）持続感染における機能的治癒を適応として、製造販売承認を取得したことをお知らせします。 本承認は、第III相B-Well 1試験およびB-Well...

3 min read time Adult vaccination plays an important role in helping protect people across the life course, yet vaccination rates in the United States remain below national public health targets. While conversations about vaccine uptake often focus on individual decision-making or patient hesitancy, new research published in Vaccine from two GSK authors underscores that the barriers to adult vaccination are broader and more complex.

Se incorporado, cabotegravir será o primeiro medicamento de longa duração para prevenção ao HIV disponível na rede pública, ampliando as opções disponíveis Rio de Janeiro, agosto de 2026 – A Consulta Pública nº 76/2026 que avalia a incorporação de cabotegravir injetável de longa duração para prevenção ao HIV no Sistema Único de Saúde (SUS) ficará aberta até o dia 31 de agosto de 2026.

スペシャリティ医薬品とワクチンの好調な業績が、売上およびコア営業利益の成長を牽引 第2四半期の総売上高は84億ポンドで、AERで5%増、CERで5%増 スペシャリティ医薬品の売上高は38億ポンド（14%増）、その内、呼吸器・免疫・炎症関連は11億ポンド（19%増）、オンコロジー関連は6億ポンド（17%増）、HIV関連は21億ポンド（10%増） ワクチンの売上高は23億ポンド（8%増）、その内、シングリックスは9億ポンド（3%増）、髄膜炎ワクチンは5億ポンド（21%増）、アレックスビーは2億ポンド（100%超増） ジェネラル医薬品の売上高は23億ポンド（9%減）、その内、テリルジーは8億ポンド（7%減） 総営業利益は75%減、1株当たり利益合計は69%減、これは、コア営業利益の増加および事業売却によるその他の収益の増加があった一方で、主にCamlipixantに関連する13億ポンドの減損損失および条件付対価に係る負債の増加により、一部相殺されたことを反映...